Seratrodast
Seratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997.
Product Specifications
CAS Number
112665-43-7
Product Name Alternative
AA2414 | A-73001 | ABT-001
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Soluble in Water
Smiles
O=C (O) CCCCCC (C (C1=O) =C (C) C (C (C) =C1C) =O) C2=CC=CC=C2
Molecular Formula
C22H26O4
Molecular Weight
354.44
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(+-) -7- (3,5,6-Trimethyl-1,4-benzoquinon-2-yl) -7-phenylheptanoic acid
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP70820-01 20 µg
Recombinant Human Transcription initiation protein SPT3 homolog(SUPT3H), partial
Sign In for Pricing
View Details 
AP70820-02 100 µg
Recombinant Human Transcription initiation protein SPT3 homolog(SUPT3H), partial
Sign In for Pricing
View Details AP70820-03 1 mg
Recombinant Human Transcription initiation protein SPT3 homolog(SUPT3H), partial
Sign In for Pricing
View Details 
